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Since the majority of high-grade breast cancers express reduced levels of BRCA1 mRNA, we investigated the
factors regulating BRCA1 transcription. Factors with speciﬁc afﬁnity for the previously identiﬁed positive
regulatory region (PRR) in the BRCA1 promoter were puriﬁed from whole-cell extracts. Identiﬁed proteins
included replication protein A and a series of related factors with afﬁnity for the sense strand of PRR. A subset
of the identiﬁed factors activated the BRCA1 promoter. Identiﬁcation of these families of proteins regulating
the BRCA1 promoter represents an important step in the comprehension of the mechanisms responsible for
breast cancer development.
Mutations of BRCA1 are thought to account for 5 to 10% of
all cases of breast cancer and approximately 50% of all cases of
inherited breast cancer. They are also suggested to be respon-
sible for 80 to 90% of all cases of cancer in families with
breast-ovarian cancer syndrome (40). Women inheriting mu-
tations in BRCA1, most of which are truncating mutations,
have an 85% chance of developing breast cancer in their life-
times (32). An interesting aspect of BRCA1 is that, although
mutations in the gene are associated with highly invasive in-
herited breast cancers, few mutations have been detected in
the BRCA1 gene in sporadic forms of cancer (17).
Interestingly, BRCA1 expression was observed to be sup-
pressed in most high-grade sporadic breast cancers (47, 50),
and it was suggested that the reduction in BRCA1 mRNA (and
protein) may be due to dysregulated transcription. Further-
more, hypermethylation of BRCA1 promoters and reduced
levels of BRCA1 transcripts in sporadic breast cancers have
been reported (3, 6, 10, 13, 15, 16, 26–28, 34, 36–38), suggesting
a role for BRCA1 in nonfamilial breast cancers.
Despite the importance of identifying factors regulating
BRCA1 transcription, scant information was available to us.
Recently, the ID4 factor was proposed to regulate BRCA1
transcription (5). Our laboratory identiﬁed a positive regula-
tory region (PRR) in the BRCA1 promoter (44). Deletion of
the PRR resulted in a signiﬁcant loss of BRCA1 transcriptional
activity. In addition, the PRR exhibited a strong and speciﬁc
afﬁnity for nuclear factors. These results were conﬁrmed by
others who demonstrated a regulatory role for the region en-
compassing the PRR (42). In the present study, we demon-
strate by mutational analysis that an intact PRR in the BRCA1
promoter is essential for BRCA1 promoter activity. We puri-
ﬁed the three subunits of replication protein A (RPA), a spe-
ciﬁc factor binding double-stranded as well as single-stranded
PRRs. We also puriﬁed and identiﬁed a family of related
factors with a speciﬁc afﬁnity for the sense strand of the PRR,
and we show evidence for these factors’ roles in regulating
BRCA1 transcription.
MATERIALS AND METHODS
Mutants of the PRR. The isolation of the BRCA1 promoter and the conditions
used for the generation of BRCA1 promoter mutants have been described pre-
viously (44). Systematic deletion mutants of the PRR were constructed by uti-
lizing PCR ampliﬁcation. Primers with systematic deletions at the 5 ends of the
PRR (202 to 178) and a 3 primer described previously were used to amplify
1n go ft h eBRCA1 promoter template. The ampliﬁed products were digested
with MluI and XhoI (restriction enzyme sites incorporated in the primers) and
ligated into pGL3 basic vector (purchased from Promega) containing the lucif-
erase reporter gene.
To generate BRCA1 promoter mutants spanning less than 100 bp, respective
DNA strands were synthesized, annealed, and ligated directly into pGL3 basic
vector. Synthetic primers with progressive 3 deletions and containing adapters of
the MluI and XhoI enzymes at each end were annealed and ligated to the MluI
and XhoI sites of the pGL3 basic vector to generate BRCA1 promoters with 3
deletions. The cyclic AMP response element binding (CREB) site was disrupted
in the transcriptionally active BRCA1 promoter fragment spanning positions
202 to 136 by incorporating mutated residues in synthetic primers, which
were ligated directly into pGL3 basic vector. Point mutations in the PRR were
generated by the ligation of synthetic annealed primers (with MluI and XhoI
adapters) in the pGL3 basic vector. All constructs were conﬁrmed by sequencing.
RPA cDNA was a gift from R. Fishel and M. Wold. RPA1- and RPA2-
expressing clones were generated by subcloning the respective cDNA clones in
the pcDNA 3.1 () vector (purchased from Invitrogen) in the EcoRI site. The
FBP-1 antibody (24) and cDNA clone of FBP-1 in the pET28a vector were gifts
from David Levens. The XbaI/HindIII fragment containing FBP-1 cDNA (ob-
tained from the pET28a construct) was subcloned in the pcDNA 3.1 () vector,
which contained the cytomegalovirus (CMV) promoter. The cDNAs of the other
factors were ampliﬁed (with the Gold Taq system purchased from Roche) from
human placental, ovarian, skeletal, brain, and lymph node cDNAs. The ampliﬁed
constructs were cloned in pcDNA3.1/V5 His Topo vector (purchased from In-
vitrogen) by using the TA cloning technique per the manufacturer’s protocol. All
the insertions were conﬁrmed by sequencing. The forward (F) and reverse (R)
primers from the respective 5 and 3 sequences are as follows: DAZAP1 F
(5-ATG AAC AAC TCG GGC GCC GAC GAG A-3) and DAZAP1 R
(5-CTA GCG TCG GTA GGG GTG GAA CC-3), ELAVL1 F (5-ACA ATG
TCT AAT GGT TAT GAA GAC C-3) and ELAVL1 R (5-GAG CGA GTT
ATT TGT GGG ACT TG-3), HN-RNPK F (5-GAA TAT GGA AAC TGA
ACA GCC AG-3) and HN-RNPK R (5-GCA TTA GAA TCC TTC AAC ATC
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3774TGC-3), HN RPA2 F (5-GAA GCG ACT GAG TCC GCG ATG-3) and HN
RPA2 R (5-GGA AGA AGC TCA GTA TCG GCT-3), PCBP1 F (5-TCG
CCA TGG ATG CCG GTG TGA CTG-3) and PCBP1 R (5-CTG TTC TAG
CTG CAC CCC ATG C-3), PCBP2 F (5-TGC TCG ACA TGG ACA CCG
GTG TG-3) andPCBP2 R (5-ATC TGC ATT GTT CTA GCT GCT C-3),
PTBP1 F (5-GTG CCA TGG ACG GCA TTG TCC-3) and PTBP1 R (5-CCC
TAG ATG GTG GAC TTG GAG-3, and TIA1-F1 (5-ATG GAG GAC GAG
ATG CCC AAG ACT C-3) and TIA1-R1 (5-CCT TAT TCA CTG GGT TTC
ATA CC-3.
Transfections, EMSAs, and Northern blot analyses. Maintenance of MCF-7
cells, transfections, luciferase assays, normalization of transfection efﬁciencies,
preparation of nuclear extracts, and electrophoretic mobility shift assays (EM-
SAs) were performed essentially as described previously (44, 45). The Ramos
B-cell lymphoma line was grown in RPMI medium supplemented with 10% fetal
bovine serum. Supershift experiments were performed by adding 1 to 5 go ft h e
antibodies indicated below to EMSA reaction mixtures. Northern blots were
performed by the hybridization of 20 g of total RNA with probes derived from
ﬁrst 80 bases of published cDNAs.
Puriﬁcation of the Py/Pu motif and PRR binding proteins. The steps followed
in protein puriﬁcation are outlined in Fig. 4. Total-cell extract was made from 15
liters of the Ramos cell line as described previously (29). The extract was
passaged over a cation-exchange column (SP Sepharose purchased from Phar-
macia) and collected as unbound Py/Pu binding activity in the ﬂowthrough. The
Py/Pu binding activity was pooled and passaged over an anion-exchange column
(Q Sepharose purchased from Pharmacia) and once again collected as unbound
activity. A third chromatography step involved passage over a DNA afﬁnity
column of double-stranded Py/Pu motif DNA as previously described (2), exten-
sive washing in increasing concentrations of potassium chloride in EMSA base
buffer up to a concentration of 1 M, and elution of bound proteins with 2 M
NaCl. After each enrichment step, eluted proteins were dialyzed in EMSA
binding buffer. The eluted proteins were analyzed by standard Coomassie blue
staining methods. The protein bands were excised from the gel and subjected to
trypsin digestion and matrix-assisted laser desorption ionization (MALDI)–mass
spectrometry identiﬁcation. Immunoblotting was performed with an ECLPlus
kit purchased from Amersham Pharmacia Biotech.
For puriﬁcation of single-stranded PRR binding proteins, an afﬁnity column of
sense-strand PRR was generated. Each synthetic primer contained two PRR
sites. The eluted fractions were monitored for PRR binding and analyzed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
MALDI.
Immunoprecipitation of PRR-protein complex. We used a method adapted
from a chromatin immunoprecipitation (ChIP) assay wherein antibodies recog-
nizing PRR binding proteins were used to immunoprecipitate the prepared
DNA-protein complex instead of antibodies recognizing histone proteins. A total
of 10
6 MCF-7 cells were ﬁxed on a petri plate with 1% formaldehyde for 10 min
at 37°C and washed with ice-cold phosphate-buffered saline solution containing
protease inhibitors (1 mM phenylmethylsulfonyl ﬂuoride, 1 g of aprotinin per
ml, and 1 g of pepstatin A per ml). This treatment resulted in covalent cross-
linking of DNA to proteins (including histones). The cells were scraped, pelleted,
suspended in 200 l of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM
Tris-HCl), incubated on ice for 10 min, and sonicated (the DNA length, kept
between 200 bp and 1 kb, was monitored by reverse cross-linking in the presence
of 5 M NaCl at 65°C for 4 h with subsequent phenol-chloroform-isoamyl alcohol
extraction and visualization with an agarose gel run). The sonicated sample was
spun for 10 min, and the supernatant was diluted 10-fold in ChIP dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl [pH 8.1],
167 mM NaCl) supplemented with protease inhibitors. The cell supernatant was
precleared by adding 80 l of salmon sperm DNA-protein A-agarose slurry (400
g of salmon sperm DNA per ml, 1 mg of bovine serum albumin per ml, and 3
mg of protein A per ml in 10 mM Tris-HCl [pH 8.0]–1 mM EDTA), incubating
it for 30 min at 4°C, and spinning to obtain a supernatant ready for immuno-
precipitation.
Approximately 5 g of antibodies recognizing RPA1, RPA2, FBP-1, and
DNA-dependent protein kinase (negative control) was added to each prepara-
tion and incubated overnight at 4°C. Sixty microliters of salmon sperm DNA-
protein A agarose slurry was added and incubated for1ha t4 °C to collect the
antibody-protein-DNA complex, which was pelleted by centrifugation at 4,000
rpm for 1 min in a Microfuge (Eppendorf). The pellet was washed sequentially
with low-salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl [pH 8.1], 150 mM NaCl), high-salt immune complex
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH
8.1], 500 mM NaCl), and lithium chloride [LiCl] immune complex wash buffer
(0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM
Tris-HCl [pH 8.1]). Finally, the antibody complex was washed twice with Tris-
HCl (10 mM, pH 8.0)–EDTA (1 mM) buffer. The complex was eluted twice from
the antibody by adding 200 l of elution buffer (1% SDS, 0.1 M sodium bicar-
bonate) and incubating it at room temperature for 15 min. The agarose beads
were spun down, and the supernatant was collected. Twenty-ﬁve microliters of 5
M NaCl was added to the supernatant, and the DNA and proteins were reverse
cross-linked by heating the mixture to 65°C for 4 h. The sample was subjected to
proteinase K digestion at 45°C for 1 h and then subjected to phenol-chloroform
extraction and ethanol precipitation. The precipitated DNA was pelleted,
washed with 70% ethanol, air dried, and dissolved in distilled water. The pres-
ence of the BRCA1 PRR element was investigated by using PCR ampliﬁcation
(35 cycles; 94, 65, and 72°C) with BRCA1 primers (5-GCC GCA ACT GGA
AGA GTA GAG-3 and 5-GAT GGG AGG GAC AGA AAG AGC-3) en-
compassing the PRR.
RESULTS
PRR. The PRR is essential for BRCA1 promoter activity (42,
44). A schematic representation of the sense strand of the
BRCA1 PRR is shown in Fig. 1A. Sequence analysis of the
PRR suggested the presence of two potential motifs within the
PRR. The 5 motif consists primarily of polypyrimidine and
polypurine (Py/Pu) bases, with a single guanine (G) base. The
second putative motif is similar to the CREB site. In addition,
a previously reported (52) transcription start site is indicated.
PRR mutants. In order to study the importance of the PRR
in BRCA1 transcription, a series of BRCA1 promoter mutants
were constructed. The transcriptional activities of the con-
structs were measured by reporter gene assays as previously
described (44). All transfections were performed in the MCF-7
breast cancer cell line.
5 promoter deletions. Mutants with systematic deletions in
the PRR site of the BRCA1 promoter were transfected in
MCF-7 cells and measured for reporter activity (Fig. 1B). The
progressive deletions impaired BRCA1 promoter activities.
Deletion of 4 bases from the 5 end of the PRR resulted in a
signiﬁcant decrease of promoter activity (202 versus 198).
Further deletions correlated with a trend of gradual decline in
activity, except in the cases of mutants 194 and 186, for
which some increase of activity was noted upon deletion of
bases. Mutants 194 and 186 provided the ﬁrst hint that
BRCA1 transcription may be complex. Deletion of the 5 half
of the Py/Pu site (deletions after position 186) resulted in
further loss of promoter activity. These results suggest the
importance of an intact Py/Pu site for promoter activity.
3 deletions. Progressive deletions from the 3 end of the
BRCA1 promoter were also made (Fig. 1C). Surprisingly, con-
structs lacking the previously reported start site showed strong
transcriptional activity comparable to that of the wild-type
promoter. Initial deletions resulted in a modest increase of
promoter activity, suggesting the presence of inhibitor se-
quences (mutants 136 to 166). Deletion of more than 6
bases from position 166 caused a signiﬁcant drop in pro-
moter activity (mutants 171 to 174). Progressive 3 deletion
experiments helped to identify a minimal fragment of 37 bp
(positions 202 to 166), which was transcriptionally active
and encompassed the PRR.
CREB site mutation. The mutants with 3 deletions in the
PRR (Fig. 1C) indicated the importance of the CREB site in
BRCA1 transcription. Deletion of 5 bases within the CREB site
(mutant 171) abolished the transcriptional activity of the
BRCA1 promoter. In order to further conﬁrm the importance
VOL. 23, 2003 BRCA1 TRANSCRIPTIONAL REGULATION 3775FIG. 1. PRR of the BRCA1 promoter, results of mutation studies, and mapping of the start site. (A) Schematic representation and sequence
of the PRR. The Py/Pu, CREB, and transcriptional start sites are indicated. The guanine residue in the Py/Pu site is indicated with an arrow. (B)
Transcriptional effects of 5 deletions in the PRR. The 3 ends of all the mutant sequences correspond to position 36 of the promoter.
Transfections were performed in triplicate for each construct and represent results from several repeats. (C) Transcriptional effects of the 3
promoter deletions. The structures and relative activities (i.e., the percentages of the level of activity of the full-length PRR sequence) are shown.
(D) Relative activity of the BRCA1 promoter with the site-directed mutation within the CREB site (indicated by the arrow). The results of panels
C and D are from three independent transfection experiments. (E) Mapping of the BRCA1 start site was performed by 5RACE. RACE-ready
cDNA from human testis cells (purchased from AMBION) was ampliﬁed with BRCA1 GSP1 (5-CCC AGT TAT CTG AGA AAC CCC ACA)
and outer adapter primer 1 (AP1, 5-GCT GAT GGC GAT GAA TGA ACA CTG-3) for 35 cycles. One microliter was reampliﬁed by using the
nested primers GSP2 (indicated in the ﬁgure) and inner adapter primer 2 (AP2, 5-CGC GGA TCC GAA CAC TGC GTT TGC TGG CTT TGA
TG-3) for 45 cycles. The ampliﬁed product was analyzed on 2% agarose gel, puriﬁed, and sequenced. Molecular size markers (in base pairs) are
noted at the left of the gel. (F) Start sites used by the BRCA1 promoter in an in vitro system. An ampliﬁed fragment of the BRCA1 promoter
(positions 58 to 246; primers used were 5-GCC GCA ACT GGA AGA GTA GA-3 and 5-AAG GCC TCC TGA GCG CAG GG-3) was
used as template DNA. The BRCA1 promoter DNA and a control of the CMV promoter (expected to transcribe a 363-bp product) were in vitro
transcribed by using HeLa nuclear extract (purchased from Promega) in the presence of radiolabeled UTP and additional ribonucleotides at 37°C
f o r1ha ssuggested by the manufacturer. The transcribed RNA was extracted with phenol-chloroform and isoamyl alcohol, ethanol precipitated,
3776 THAKUR ET AL. MOL.C ELL.B IOL.and resolved in 10% Tris-borate-EDTA gel. Reverse transcription of the transcribed RNA was performed with avian myeloblastosis virus reverse
transcriptase (purchased from Fisher Scientiﬁc) in the presence of radiolabeled cytosine. The products were electrophoresed in a 6% Tris-borate-
EDTA–urea gel with dideoxy sequencing reactions (with the fMol sequencing kit from Promega) by using GSP2 with a BRCA1 promoter construct
as a template. (G) Mapping of the start site(s) of the minimal BRCA1 promoter within the reporter gene vector. A construct with the BRCA1 PRR
(described in the legend to Fig. 3) was used as a template to amplify a segment encompassing the PRR by utilizing vector-based primers (RV
Primer 3 and the luciferase-speciﬁc primer indicated in the sequence). Start sites were mapped by primer extension analysis of transcribed
luciferase RNA with a second luciferase-speciﬁc primer (5-TTA TGC AGT TGC TCT CCA GC-3). Increasing quantities of primer extension
reaction mixtures were loaded in the lanes from left to right. The locations of the multiple cloning site (MCS) of the vector, the BRCA1 PRR, and
the transcription start site are indicated. The luciferase coding region is in uppercase and italicized. Vector sequences are in lowercase, and the
BRCA1 promoter is in uppercase.
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tions 202 to 136) in which the CREB site was mutated. A
mutation of the ﬁrst 3 bases (ACG) of the CREB site to
thymidines resulted in signiﬁcantly decreased activity (Fig.
1D). In addition, the introduction of point mutations (see Fig.
3) (mutants P15 to P19) within the CREB site also impaired
transcriptional activity.
The results suggested that the PRR may function as an
enhancer for the cryptic promoter(s) present within the re-
porter gene vectors. However, it was observed that the PRR
was orientation and position dependent, that it did not activate
a heterologous promoter (data not shown), and therefore that
it did not ﬁt the classic deﬁnition of an enhancer. Another
possibility was that the BRCA1 promoter was encompassed
within the PRR and that it used an alternative site(s) (distinct
from the ones reported) for transcription initiation.
Transcriptional start sites of the BRCA1 promoter. The
possibility of an alternative start site(s) in close proximity to
the PRR was investigated by using rapid ampliﬁcation of the 5
cDNA ends (5RACE). Initially, our attempts to identify the
BRCA1 transcription start site were confounded by ampliﬁca-
tion of the 5 ends of transcripts derived from the BRCA1
pseudogene (8; data not shown). Therefore, primers were de-
signed by taking into account the expression of transcripts
derived from the pseudogene. Template cDNAs derived from
human testes were used, as testes express the highest level of
BRCA1 transcripts (46). Ampliﬁcations resulted in the detec-
tion of cDNA moieties which were detected as two bands of
160 and 90 bases (Fig. 1E, left panel). The cDNAs were sub-
cloned and sequenced. Four potential start sites were mapped
by this method and are indicated. Since the 160-bp cDNA was
predominant and represented the site upstream of all the re-
ported (and detected) sites, it was used for marking the start
site in subsequent descriptions. This start site (labeled number
1) is 21 bases downstream of the 3 end of the transcriptionally
active PRR. The 5end of PRR was accordingly renumbered at
58.
In addition to 5RACE, primer extension experiments with
in vitro-transcribed RNA expressed from the BRCA1 promoter
were performed. As a promoter template, an ampliﬁed prod-
uct containing the PRR, the newly mapped start sites, and 241
downstream bases (Fig. 1F, upper-left panel) was transcribed
with HeLa nuclear extracts. A control lane expressing a prod-
uct (363 bp) transcribed by the CMV promoter was included
(lane 1, upper-right panel). BRCA1 promoter-transcribed
products consistent with approximate sizes of 180 to 200 bp
were detected (lane 2). It proved difﬁcult to map the 5 resi-
dues of these RNAs directly by comparison with sequences
from sequencing reactions due to RNA degradation in the
sequencing gels. Therefore, primer extension experiments
(performed by using gene-speciﬁc primer 2 [GSP2]) were used
to generate more-stable cDNAs (lower-left panel). The in
vitro-transcribed RNAs were reverse transcribed in the pres-
ence of radiolabeled UTP. The radiolabeled cDNAs were elec-
trophoresed in a sequencing gel with dideoxy sequencing re-
action mixtures containing the BRCA1 promoter by using
GSP2 (data not shown). Eight start sites were detected and are
indicated (lower-right panel). Interestingly, only one start site
(site number 5) was identical to the one identiﬁed by 5RACE
(site number 4 of Fig. 1E). The transcription start site was not
detected within the PRR itself, suggesting that basal transcrip-
tion machinery assembles within the PRR and initiates tran-
scription 21 to 100 bases downstream of the PRR. Deletion of
promoter bases downstream of the PRR does not inhibit pro-
moter activity (Fig. 1C), suggesting that the PRR is utilized for
assembly and priming of the basal machinery, which subse-
quently initiates transcription by using downstream nonspeciﬁc
vector sequences.
In order to map the start sites used in reporter constructs by
BRCA1 promoters with 3 deletions, additional 5 mapping
experiments were performed (Fig. 1G). An ampliﬁed product
containing the BRCA1 PRR, vector sequences, and a section of
the luciferase reporter gene (shown in the sequence) was used
as template DNA and transcribed. Transcripts of variant sizes
were detected (data not shown), and the 5 ends of these
products were mapped by primer extension analysis (upper
panel). The experiments suggested the presence of a start site
(5-TTCCG.... )i nt h evector sequence upstream of the lucif-
erase cDNA. Additional higher-mobility bands reﬂecting start
sites in the coding region of luciferase cDNA were also de-
tected (data not shown), though the derivative RNAs would
not be translated into full-length luciferase proteins.
BRCA1 promoter or PRR binding studies. The double-
stranded PRR was used as a probe with MCF-7 (breast cancer
cell line) nuclear extracts in EMSAs (Fig. 2A). Diffuse DNA-
protein complexes were observed (lane 2). Competition with
nonspeciﬁc oligonucleotides had no signiﬁcant effect on DNA-
protein complexes (lane 3). In contrast, speciﬁc competitors
abolished the complexes (lane 4).
EMSAs with DNA probes derived from the Py/Pu and
CREB sequences were performed to characterize the factors
that bound these sites individually. The Py/Pu probe formed
distinct DNA-protein complexes (Fig. 2B, lane 2). These com-
plexes were not affected by nonspeciﬁc competition (lane 3).
Speciﬁc competition disrupted the DNA-protein complexes
(lane 4). Thus, Py/Pu protein binding was speciﬁc.
Although speciﬁc protein binding to the CREB site has been
reported previously (28), we did not detect protein binding
(data not shown), suggesting that CREB binding may be cell
line speciﬁc. Signiﬁcantly, mutations in the CREB site resulted
in downregulation of promoter activity (Fig. 1D and 3), indi-
cating the functional importance of the motif. Therefore, the
CREB site may function in protein binding in the context of
the full-length PRR.
EMSAs with double-stranded Py/Pu domain constructs and
competitions with oligonucleotides with progressive deletions
matching the deletion promoter constructs in Fig. 1B were
performed (Fig. 2C). Incubation of the probe with the MCF-7
nuclear extract resulted in a distinct DNA-protein complex
(lane 2). Competition with a nonspeciﬁc probe had no effect
(lane 3), while speciﬁc competition abolished the DNA-protein
complex (lane 4). Competitions with oligonucleotides with pro-
gressive deletions showed a progressive loss in the ability of
these oligonucleotides to compete for protein binding (lanes 5
to 13). The decreases in the binding afﬁnities of competing
mutant oligonucleotides were largely concordant with the loss
of mutant promoter activities. These experiments reinforced
the importance of an intact Py/Pu motif for normal activity of
the BRCA1 promoter. Interestingly, we occasionally detected
diffuse and streaked high-mobility DNA-protein complexes.
3778 THAKUR ET AL. MOL.C ELL.B IOL.FIG. 2. PRR binding studies. (A and B) EMSA was performed with PRR (A) and Py/Pu (B) probes. Speciﬁc (S) competitions were performed
with a 100-fold excess of double-stranded, annealed, and unlabeled PRR and Py/Pu oligomers. The arrow in panel B indicates the distinct DNA-protein
complexes formed by the Py/Pu probe. Nonspeciﬁc (NS) competition was performed with a synthetic oligomer (5-GTC ACT ATG GCT TTC AAT TGG
CCC GGC ATA G-3) annealed to its complementary sequence. (C) DNA binding afﬁnities of mutant constructs with systematic deletions in the PRR.
Nonspeciﬁc (NS) and speciﬁc (S) competitions were performed with the CREB and Py/Pu oligomers, respectively. Additional competitions were
performed with the Py/Pu oligomers with systematic 5 deletions. The long arrow indicates the distinct DNA-protein complex formed by the MCF-7
nuclear extract. The short arrow indicates diffuse and streaked high-mobility DNA-protein complexes. N.E., nuclear extract; DS, double stranded.
VOL. 23, 2003 BRCA1 TRANSCRIPTIONAL REGULATION 3779Point mutations of the PRR domain. Identiﬁcation of the
functional BRCA1 transcriptional unit provided us with a
reagent with which to perform a rapid mutation analysis of this
region (Fig. 3). The template used for mutagenesis ranged
from positions 58 to 10 (extra bases were included to pro-
vide ﬂanking sequences). Sequential dinucleotide and mono-
nucleotide point mutations were introduced across the PRR
(Fig. 3A). Strikingly, the majority of mutants demonstrated
signiﬁcant loss of activity compared to that of the wild type
(Fig. 3B). Particularly, mutations in the center of the Py/Pu
domain (P6 to P9) caused a loss of over 95 to 99% of the
activity. Mutations in the CREB site (P15 to P19) resulted in a
decline of 90 to 95% of promoter activity (except P18). The
mutagenesis studies suggested the existence of a complex
mechanism inﬂuencing BRCA1 transcription in which regula-
tion was dependent upon the recruitment of multiple proteins
to the PRR. Thus, efforts to identify PRR binding factors were
initiated.
Puriﬁcation of PRR binding factors. Chromatographic pro-
tocols were followed to enrich the PRR binding factors (Fig.
4). Ramos B-cell leukemic cells were used to prepare total-cell
extracts, as this cell line could be grown rapidly in large vol-
umes, as opposed to adherent breast cell-derived lines. The
approach was adopted with a view to extending the results of
these studies to breast cells. As shown below, Ramos and
MCF-7 cells exhibited similar PRR binding activities (see Fig.
6A, MCF-7 versus Ramos cell input).
Initial enrichment of the 300-mg total extract was performed
by cation (SP Sepharose)- and anion (Q Sepharose)-exchange
chromatography, and the PRR binding activity was monitored
by EMSA (data not shown). As the Py/Pu region was observed
to be important in BRCA1 promoter function (Fig. 1B) and
FIG. 3. Transcriptional activities of PRR point mutations. (A) The mutated bases in the PRR are in lowercase, italicized, and boldface letters.
(B) Transcriptional activities of PRR point mutations. The vector control (pGL3 basic) is indicated. WT, wild type.
3780 THAKUR ET AL. MOL.C ELL.B IOL.also demonstrated speciﬁc protein binding (Fig. 2B and C),
double-stranded Py/Pu binding proteins were puriﬁed and
identiﬁed as the RPA factor. As it was subsequently observed
that single-stranded PRR had a speciﬁca f ﬁnity for proteins, a
second round of DNA afﬁnity chromatography with single-
stranded PRR was used to purify the binding factors (shown
below).
Puriﬁcation and characterization of double-stranded Py/Pu
binding proteins. The eluted Py/Pu binding activity was ana-
lyzed by SDS-PAGE and Coomassie blue staining. Three pro-
teins with molecular sizes of 70,000, 34,000, and 14,000 (p70,
p34, and p14, respectively) were observed (Fig. 5A). These
bands were excised and identiﬁed by trypsin digestion and
MALDI–mass spectrometry. The three proteins constitute a
trimer of the RPA factor (with p70 being equivalent to RPA1,
p34 being equivalent to RPA2, and p14 being equivalent to
RPA3) and have previously been shown to be essential for
DNA replication initiation (51).
RPA is known to have speciﬁc single-stranded DNA binding
activity and an apparent afﬁnity for double-stranded DNA
(22). These results suggest that single-stranded DNA binding
factors such as RPA may bind to the PRR, although earlier
studies were all performed with annealed, double-stranded
probes. Therefore, EMSAs were performed with a probe made
from the sense strand of PRR and MCF-7 nuclear extracts
(Fig. 5B). Strong binding of proteins to the single-stranded
PRR was observed in the MCF-7 extract (lane 2). Competition
studies indicated that the protein binding was speciﬁc (lanes 3
and 4). In contrast to the sense-strand PRR probe, the anti-
sense PRR probe did not exhibit speciﬁc protein binding (data
not shown).
To conﬁrm that puriﬁed RPA factor eluted from the double-
stranded Py/Pu column bound the single-stranded PRR, addi-
tional EMSAs were performed (Fig. 5C), and two DNA-
protein bands were detected (lane 2). Monoclonal antibodies
recognizing RPA were added to EMSA reaction mixtures
(lanes 3 to 5). Ab1 (anti-p70) caused increased DNA-protein
binding (lane 3), and the Ab2 and Ab3 (anti-p34) antibodies
supershifted the DNA-protein complexes (lanes 4 and 5),
thereby conﬁrming RPA’s binding to the PRR. The addition of
unrelated antibody had no effect on the DNA-protein complex
(data not shown). Competition studies with speciﬁc and non-
speciﬁc oligonucleotides indicated that the binding was speciﬁc
(lanes 6 and 7).
An additional supershift experiment with MCF-7 nuclear
extracts and Ab3 antibody suggested the presence of RPA2 in
the single-stranded PRR DNA-protein complex formed (Fig.
5D, lane 3).
Puriﬁed RPA bound double-stranded Py/Pu as expected
(lane 2), since it was used as bait to purify RPA, and the
resultant DNA-protein complex was supershifted by Ab3 an-
tibody (Fig. 5E, lane 3). The afﬁnity of RPA for single- as well
as double-stranded DNA suggests a speciﬁc role of RPA in the
binding and unwinding of double-stranded DNA. Cotransfec-
tions with RPA-expressing constructs had no signiﬁcant effect
on BRCA1 promoter activity (data not shown), suggesting that
RPA’s effects on BRCA1 transcription may involve complex
protein interactions and/or modiﬁcations which are discussed
below.
Though RPA factor bound the PRR, several lines of evi-
dence suggested that RPA factor alone was not involved in
PRR binding and the regulation of BRCA1 transcription. Sig-
niﬁcantly, site-directed mutation studies suggested the exis-
tence of multicomponent transcription regulation through the
PRR (Fig. 3). In addition, the large PRR-protein complexes
formed in EMSAs with a single-stranded PRR probe were not
consistent with RPA binding alone (Fig. 5B). RPA2 antibody
did not supershift the bulk of the DNA-protein complex, sug-
gesting that the majority of PRR binding factors were not RPA
(Fig. 5D). Finally, whereas the full-length PRR was essential
for BRCA1 promoter function, RPA bound to a subset of the
PRR, the Py/Pu motif. To reconcile these inconsistencies and
to further clarify the regulatory process of BRCA1 transcrip-
FIG. 4. Outline of steps used in the puriﬁcation of PRR binding factors. Washes and elutions, unless otherwise indicated (when a solution of
sodium chloride [NaCl] was used), were performed with a molar solution of potassium chloride (KCl). DS, double stranded; SS, single stranded.
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full-length PRR.
Puriﬁcation and characterization of single-stranded PRR
binding proteins. In the puriﬁcation procedure, single-strand-
ed PRR binding activity eluted as an unbound form from the
Py/Pu double-stranded DNA afﬁnity column (Fig. 4). This ac-
tivity was pooled and passaged through a single-stranded PRR
afﬁnity column, washed with 0.1 M KCl, and step eluted with 2
FIG. 5. Puriﬁcation and characterization of Py/Pu binding proteins.
(A) Eluted fractions were analyzed by SDS-PAGE and Coomassie blue
staining. Each fraction collected from the DNA afﬁnity column was elec-
trophoresed in two lanes. Numbers at the left are molecular weight
(MW) markers (in thousands). (B) Single-stranded PRR-speciﬁc bind-
ing was assessed by using MCF-7 nuclear extract. Nonspeciﬁc (NS) (5-
CAA GCG GCC ATC TTG GGT CCA AGC GGC CAT CTT GGG
T-3) and speciﬁc (S) competitions were performed. (C) Supershift
experiments with RPA antibodies. Monoclonal antibodies (Ab1, Ab2,
and Ab3, purchased from Oncogene Research) were used in supershift
assays. The speciﬁcities of DNA-protein complexes were tested by non-
speciﬁc and speciﬁc competitions. (D) Supershift experiment with Ab3
antibody and MCF-7 nuclear extract. (E) Binding of puriﬁed proteins
to the double-stranded Py/Pu probe and supershifting by Ab3. SS, sin-
gle stranded; DS, double stranded; Ab, antibody; N.E., nuclear extract.
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activity (Fig. 6A). In addition, as controls, EMSAs were per-
formed with MCF-7 nuclear extracts and the input fraction.
Signiﬁcantly, the PRR-protein complexes formed by factors
from Ramos (input) and MCF-7 lines were similar. This result
suggested similarity in the compositions of the PRR binding
proteins in Ramos and MCF-7 cells. Speciﬁc PRR binding
activity, which was similar to that generated by partially puri-
ﬁed input, was recovered from the afﬁnity column (lane 4 of
eluted fractions).
Four eluted fractions were analyzed by SDS-PAGE and
Coomassie blue staining, followed by identiﬁcation of stained
protein bands by the MALDI procedure (Fig. 6B). The 10 pro-
teins identiﬁed by this method included far-upstream element
(FUSE) binding proteins 1 and 2 (FBP-1 and -2) (12), hetero-
geneous nuclear ribonucleoprotein K (hnRNP K) (31), poly-
pyrimidine tract-binding protein (PTBP) (18, 35), deleted-
in-azoospermia-associated protein (DAZ AP) (49), T-cell
intercellular antigen 1 (TIA-1) (1), poly(ribocytosine) binding
proteins 1 and 2 (PCBP-1 and -2) (48), hnRNP A2 (9, 20), and
ELAV-like protein (25). Many of these proteins are known to
bind RNA and regulate its processing. Interestingly, FBP-1,
FBP-2, and hnRNP K have been demonstrated to be DNA
binding proteins as well and are known to possess transcrip-
tion-regulatory activities (14). Signiﬁcantly, they were reported
to regulate the expression of c-Myc, a protein critical in the
regulation of human malignancies. The hnRNP C-like protein
(which was also detected as a PRR-associated protein [data
not shown]) has also been reported to activate the transcrip-
tion of hepatitis B virus enhancer II (43).
As FBP-1 is known to regulate c-Myc promoter activity and
was present in the fractions containing factors with afﬁnity for
the BRCA1 transcriptional regulatory site, we investigated its
role in BRCA1 promoter activity. The presence of FBP-1 in the
fraction eluted from the single-stranded PRR column was con-
ﬁrmed by immunoblot analysis (Fig. 6C), and two major iso-
forms (60 and 65 kDa) were observed (left panel). Similar
results were also obtained by immunoblotting MCF-7 nuclear
extracts (right panel). Furthermore, the addition of FBP-1
antibody to EMSA mixtures with a single-stranded PRR probe
and eluted fraction (from single-stranded PRR column) re-
sulted in increased protein binding and supershifting (Fig. 6D,
lane 3). An unrelated antibody had no effect on the DNA-
protein complex (lane 2). These experiments conﬁrmed the
presence of FBP-1 in the factors binding the PRR. Initial
cotransfection experiments with FBP-1 with short segments of
the BRCA1 promoter showed no effects (data not shown).
However, when FBP-1 was coexpressed with larger segments
of the promoter, transcription was suppressed (see below).
Correlation of expression patterns of BRCA1 and PRR
binding factors. The expression pattern of BRCA1 and tran-
scripts of puriﬁed proteins were investigated in a panel of
breast cancer cell lines (Fig. 6E). Immunoblot analyses were
performed with BRCA1 antibody with the nuclear extracts of
the indicated cell lines. A 220-kDa band (consistent with the
size of BRCA1 protein) was detected in the MCF-7 cells (lane
1). The BRCA1 protein was expressed at signiﬁcantly reduced
levels in MDM-MB-231, T47D, and ZR-75-1 cells (lanes 2 to
4). The protein was detected upon prolonged exposure (data
not shown). The amount of loaded protein was normalized by
actin blotting and staining of the ﬁlters with Ponsceau S during
the immunoblot procedures (data not shown).
The potential coordinate expression of BRCA1 and puriﬁed
factors was investigated. Northern blotting was performed with
probes derived from cDNA sequences of puriﬁed proteins.
Sizes of the transcripts (in kilobases) are indicated (Fig. 6E).
Signiﬁcantly, all the genes tested were expressed robustly in the
BRCA1-positive MCF-7 line and never at levels less than those
in lines with reduced BRCA1 expression (Fig. 6E, lane 1 versus
lanes 2 to 4). Signiﬁcant alteration in the expression of FBP-1,
hnRNP KA, and DAZ AP transcripts were not apparent in the
cell lines studied. Variously reduced expression of FBP-2,
PTBP-1, TIA-1, hnRNP A2, PCBP-2, and HuR was noted in
the MDM-MB-231, T47D, and ZR-75-1 lines. Strikingly,
PCBP-1 transcripts showed reduced expression in all breast
cells expressing diminished quantities of the BRCA1 protein.
This ﬁnding also suggested decreased expression of PCBP-1
protein in the indicated cell lines. Therefore, immunoblotting
was performed with PCBP-1 antibody to conﬁrm the possibility
(Fig. 6E, right panel). A 40-kDa protein consistent with the
size of PCBP-1 was observed in the MCF-7 cells. Reduction of
the steady-state level of p40 was observed in the MDM-MB-
231, T47-D, and ZR-75-1 cells.
PRR binding factors and BRCA1 transcription. The inﬂu-
ence of puriﬁed factors on BRCA1 transcription was investi-
gated. In the ﬁrst series of experiments, immunoprecipitation
assays (adapted from the ChIP assay) with extracts from
MCF-7 cells were performed with FBP-1 and RPA antibodies
(Fig. 7A). The puriﬁed DNAs procured after the immunopre-
cipitation procedures (described in Materials and Methods)
were subjected to PCR ampliﬁcation with primers encompass-
ing the PRR. The negative-control extract (immunoprecipita-
tion with nonspeciﬁc DNA-PK antibody) was not ampliﬁed
(lane 1). In contrast, after immunoprecipitation with FBP-1
and RPA antibodies, an ampliﬁed product of the expected size
was observed (lanes 2 to 5). The experiment indicates the
association of the FBP-1 and RPA antibodies with chromatin-
bound PRR.
Finally, the full-length BRCA1 promoter construct was co-
transfected with cDNA expression constructs of PRR binding
factors (Fig. 7B). It was observed that a subset of factors (DAZ
AP, hnRNP Ka, hnRNP Ka2, PCBP-1, PCBP-2, and TIA-1)
exhibited a mild but consistent activation of the promoter. The
expression construct of PTBP-1 was noted to have a relatively
strong (fourfold increase) positive effect. In contrast, FBP-1
showed a mild, yet consistent, suppressive effect on promoter
activity. PCBP-2 and ELAV did not exhibit any effect on
BRCA1 transcription. Cotransfected vector controls, pcDNA
3.1 V5 His Topo and pcDNA 3.1, did not elicit any response.
The transfection experiment was performed twice indepen-
dently to corroborate the results.
DISCUSSION
It is accepted that the loss of function of the BRCA1 gene
contributes to the development of breast cancer. Signiﬁcantly
reduced levels of BRCA1 mRNA in the majority of high-grade
breast cancer cases suggest aberrant transcription. Therefore,
studies were carried out to elucidate the factors regulating
BRCA1 promoter function. Results of the present study indi-
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binding single-stranded DNA. These factors include RPA and
a family of proteins which are also known to bind RNA. A
subset of these proteins are known to bind speciﬁc DNA se-
quences and to direct transcription.
The demonstration that BRCA1 transcription is regulated by
a speciﬁc single-stranded sequence is supported by previously
reported results of similar studies of a eukaryotic promoter
(14, 23). Speciﬁcally, it has been shown that FBP-1 and -2 and
hnRNP K bind to the positive cis-acting sequence (far-up-
stream element) on one strand of the human c-Myc gene and
promote transcription. The binding to PRR likely involves the
displacement of the nonspeciﬁc band and the binding of the
speciﬁc sense-strand sequences. The higher-mobility bands fre-
FIG. 6. Puriﬁcation and characterization of factors binding the PRR sense strand. (A) Fractions eluted from the single-stranded PRR afﬁnity
column were analyzed by EMSA with a single-stranded PRR probe. An EMSA was also performed with MCF-7 nuclear extracts (N.E.) and
partially puriﬁed input. (B) The eluted fractions (collected from the single-stranded PRR afﬁnity column) were analyzed by SDS-PAGE and
Coomassie blue staining. The identiﬁed proteins are indicated. MW1 and MW2, molecular weight markers. (C) Immunoblot of the puriﬁed PRR
binding fraction and MCF-7 nuclear extract (NE) with FBP-1 antiserum. (D) Supershift experiment with FBP-1 antiserum and puriﬁed proteins.
Unrelated antibody recognizing DNA-dependent protein kinase (N-20, purchased from Santa Cruz) was also applied as a control. SS, single
stranded. (E) Immunoblot and Northern blot analyses of the indicated proteins and genes. Immunoblotting was performed with BRCA1 D-9 and
PCBP-1 rabbit polyclonal antibody. Northern blotting was performed by using probes derived from the respective cDNAs. RNA quantity was
normalized by Northern blotting with the actin probe and by visualization of ethidium bromide-stained RNA bound to the nitrocellulose ﬁlter.
Representative panels for actin blots as well as for stained RNA shown. Numbers at the left (B and C) and to the right (E) of the Northern blots
indicate molecular size markers (in kilobases).
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form due to strand displacement and binding of the probe to
single-stranded DNA binding factors (Fig. 2C).
The binding of multiple proteins (including RPA) to the
PRR suggests complex regulation of BRCA1, consistent with
the upregulation of BRCA1 in developing cells with a rapid
rate of proliferation (21, 30). Interestingly, gel ﬁltration exper-
iments indicate that these proteins do not form a single com-
plex but rather form several multimeric complexes (ranging
from 40 to 170 kDa), which appear to independently compete
(or cooperate) in binding to the PRR (data not shown). Add-
ing complexity to the spectrum of related factors associated
with the PRR is the fact that this gamut of proteins is subject
to transcriptional, posttranscriptional, and posttranslational al-
terations. The complex and multicomponent assembly of these
single-stranded DNA binding modular proteins on the PRR
and alterations in them may be developmentally regulated and
tissue speciﬁc. The essence of regulation is likely to involve
complex interactions of multiple components aggregating on
the PRR.
The strong expression of these genes in MCF-7 cells, in
relation to expression levels in other breast cell lines, supports
the possibility of a role for these proteins in BRCA1 transcrip-
tion (Fig. 6E, lane 1 versus lanes 2 to 4). One of the proteins,
PCBP-1, which has a positive inﬂuence on BRCA1 transcrip-
tion, had reduced expression in lines expressing reduced
BRCA1. Interestingly, PCBP-1 and PTBP-1 (which has a
greater inﬂuence on BRCA1 transcription) are known to pos-
sess afﬁnity for pyrimidine-rich nucleotide sequences (11), an
observation consistent with their role in associating with the
FIG. 6—Continued.
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suggested to inﬂuence the transcription of growth-related
genes like Myc and Ras (39); it may also play a role in the
development of normal breast cells as well as breast cancer
cells. Interestingly PTBP-1 transcripts were observed to be
expressed in low quantities in two of the three lines (MDM-
MB-231 and T47-D) with reduced BRCA1 transcripts (Fig.
6E).
BRCA1 is known to be cell cycle regulated in cells grown in
tissue culture (19) and upregulated in proliferating cells un-
dergoing the process of differentiation and maturation. These
reports make the notion that DNA replication may inﬂuence
BRCA1 transcription an attractive one. Puriﬁcation of RPA as
a PRR binding factor that is essential for replication initiation
supports this model. The afﬁnity of RPA for the PRR suggests
that replication and BRCA1 transcription may be directly
linked. The processes of replication and transcription are
known to inﬂuence each other (33, 41). RPA and other PRR
binding factors may participate and interact in a replication
initiation-transcription activation complex, which may be dy-
namically regulated in proliferating cells undergoing matura-
tion. A speciﬁc role of RPA in binding and unwinding double-
stranded DNA is also plausible.
It has been suggested that single-stranded factors binding
their target site may be coupled with torsional stress due to
transcription at nearby promoters (4, 14, 23). The accumula-
tion of supercoils generated by the activity of nearby promoters
may be released by generating single strands. Speciﬁc protein
binding to unwound DNA may stabilize the single strands and
contribute to the release of transcriptionally generated super-
coiling. Since the BRCA1 promoter is known to be in proximity
to the IAI-3B gene (7), transcription of IA1-3B may augment
torsional stress on the PRR and generate single strands. In
addition to alleviating torsional stress, components of the PRR
binding factors are likely to inﬂuence basal transcription ma-
chinery as well. It is already known that FBP-1 interacts with a
transcription repressor, which associates with TFIIH in initia-
tion complex (23, 24). Therefore, FBP-1’s suppressive effect
may be partially mediated through the function of TFIIH.
In summation, the speciﬁc binding of RPA and single-
stranded DNA binding factors, coupled with changes in the
torsional stress of DNA, may introduce topological changes
which could alter and inﬂuence interactions between the PRR-
protein complexes and the associated basal transcription ma-
chinery. These complex interactions would most likely be af-
fected by changes in the states of chromatin during cell cycling
and development.
The involvement of single-stranded DNA binding factors in
BRCA1 transcription suggests a role for these proteins in
breast cell development. It also suggests that aberrant function
or expression of these proteins may contribute to the loss of
BRCA1 transcription and lead to the development of a neo-
plastic phenotype. Since PRR binding proteins also bind to
RNA, defects in them may also result in aberrant RNA pro-
cessing and thereby result in abnormal gene expression. Inves-
tigation of this functional molecular cascade of single-stranded
DNA binding proteins may yield information with regard to
the development of breast cancer.
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